In recent quarters, dealmaking has picked up noticeably, despite there not being any big-ticket acquisitions. The cash holdings of several large pharmaceutical companies have also swelled, giving them greater resources to pursue dealmaking.
INCLUDED IN THIS TRENDLINE
- After a lengthy drought, could biotech M&A be on the upswing?
- The top questions facing biotech M&A in 2022
- Venture investors turn to safer bets after biotech correction